T cell therapy has shown remarkable promise in multiple malignancies including melanoma and Acute Lymphoblastic Leukemia (ALL). Recent data demonstrated the differential efficacy of various subsets of T-helper cells in tumor regression. Th9 cells, the new member of T helper cell family, possess superior anti-tumor activity compared to Th1 and Th2 cells in murine model of melanoma. Therefore, it is important to examine the anti-tumor activity of specific subsets of Th cells in tumor models. Here, we describe the methodology of examining the anti-tumor activity of Th9 cells in murine model of melanoma.
Keywords: B16-OVA; Murine model of melanoma; T cell therapy; Th9 cells.